CAJ | 학술논문

目的探讨利拉鲁肽对非糖尿病肥胖男性心血管危险因素的影响.方法选取体质量指数＞25 kg/m2的非糖尿病肥胖男性10例为研究对象,给予利拉鲁肽治疗6个月.于用药前后评价心血管危险因素.结果 10例患者治疗前后体质量和血压差异无统计学意义(P均＞0.05).腰臀比治疗后与治疗前比较(0.98±0.04与0.94±0.04)下降,糖化血红蛋白[(5.96±0.46)％、(5.45±0.25)％]下降,高密度脂蛋白胆固醇[(1.08±0.16)、(1.24±0.15) mmol/L]和超氧化物歧化酶[(83.2±9.2)、(92.6±6.1)U/ml]较治疗前升高,差异均有统计学意义(t值分别为2.391、4.115、2.843、2.490,P均＜0.05).结论利拉鲁肽治疗后虽未见明显体质量下降,但受试者体脂分布发生改变,肥胖男性存在的心血管危险因素得到改善.
목적 탐토리랍로태대비당뇨병비반남성심혈관위험인소적영향.방법 선취체질량지수＞25 kg/m2적비당뇨병비반남성10례위연구대상,급여리랍로태치료6개월.우용약전후평개심혈관위험인소.결과 10례환자치료전후체질량화혈압차이무통계학의의(P균＞0.05).요둔비치료후여치료전비교(0.98±0.04여0.94±0.04)하강,당화혈홍단백[(5.96±0.46)％、(5.45±0.25)％]하강,고밀도지단백담고순[(1.08±0.16)、(1.24±0.15) mmol/L]화초양화물기화매[(83.2±9.2)、(92.6±6.1)U/ml]교치료전승고,차이균유통계학의의(t치분별위2.391、4.115、2.843、2.490,P균＜0.05).결론 리랍로태치료후수미견명현체질량하강,단수시자체지분포발생개변,비반남성존재적심혈관위험인소득도개선.
Objective To explore the effects of liraglutide on cardiovascular in obese men without diabetes mellitus.Methods Ten obese men without diabetes mellitus (body mass index (BMI) ＞ 25 kg/m2)were enrolled in this study.All subjects received 6 months treatments of liraglutide.Cardiovascular risk factors were measured at 0 and 6 months after treatment.Results Compared to the baseline,BMI and blood pressure didn't change(P＞0.05).The waist-hip ratio and hemoglobin A1c (HbA1c) in base line were 0.98±0.04,(5.96± 0.4) 6％,significant different from those after treatment (0.94 ± 0.04,(5.45 ± 0.25) ％;t =2.391,4.115;P＜0.05).The high density lipoprotein cholesterol and superoxide dismutase after treatment were (1.24 ±0.15) mmol/L and (92.6±6.1) U/ml,higher than those before treatment ((1.08±0.16) mmol/L,(83.2 ± ±9.2) U/ml;t =2.843,2.490;P ＜ 0.05).Conclusion Liraglutide improve body fat distribution and cardiovascular risk factors in obese men.